Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
MEN1 has no menin-restoring or pathway-directed therapy; PanNET progression remains the main cause of death, addressed by earlier detection and NET therapies.
Timing and extent of pancreatic surgery in MEN1: prospective registries are comparing strategies.
Resistance to selpercatinib (RET solvent-front mutations): next-generation RET inhibitors are in trials.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Lifelong surveillance costs and psychological burden in carriers identified as children.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
PFS HR 0.
Hadoux and colleagues, NEJM.
A milestone in how this cancer is treated.
Prophylactic total thyroidectomy timed by ATA risk level (highest risk within the first year, high risk before age 5, moderate risk guided by calcitonin); annual screening for pheochromocytoma and hyperparathyroidism.
A milestone in how this cancer is treated.